|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Guest Editorial: Back to the Beginning
Author(s)Stefan Schuber
by Stefan Schuber, U.S. Pharmacopeia
Advertisement
Articles in this issue
about 23 years ago
Inside Washington: Major Changes Ahead for FDAabout 23 years ago
Bioinformatics Databases ? Questions of Copyrightabout 23 years ago
European Editor's Report ? An Industry Comes of Ageabout 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationabout 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Mitigation and Maintenance Protect Against Future Risk
2
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
3
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
4
New Cord Blood Stem Cell Approval Alters Biopharma Manufacturing Priorities
5
